Hsp90 Inhibition Increases P53 Expression and Destabilizes MYCN and MYC in Neuroblastoma

Overview

Journal Int J Oncol

Specialty Oncology

Date 2010 Nov 27

PMID 21109931

Citations 39

Authors

Paul L Regan

Joshua Jacobs

Gerald Wang

Jaime Torres

Robby Edo

Jennifer Friedmann

Xao X Tang

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is a childhood cancer that exhibits either a favorable or an unfavorable phenotype. MYCN and MYC are oncoproteins that play crucial roles in determining the malignancy of unfavorable neuroblastoma. The Hsp90 superchaperone complex assists in the folding and function of a variety of oncogenic client proteins. Inhibition of Hsp90 by small molecule inhibitors leads to the destabilization of these oncogenic proteins and consequently suppresses tumor malignancy. Nonetheless, little is known about the effect of Hsp90 inhibition on the stability of MYCN and MYC proteins. In this study, we investigated the effect of Hsp90 inhibition on the phenotype of unfavorable neuroblastoma cells including its effect on MYCN and MYC expression. Two MYCN-amplified neuroblastoma cell lines (IMR5 and CHP134) and two non-MYCN-amplified cell lines (SY5Y and SKNAS) were used to address the effect of Hsp90 inhibition on the malignant phenotype of neuroblastoma. It was found that Hsp90 inhibition in neuroblastoma cell lines resulted in significant growth suppression, a decrease in MYCN and MYC expression, and an increase in the expression of p53. In the TP53-mutated SKNAS cell line, Hsp90 inhibition enhanced the expression of the favorable neuroblastoma genes EFNB2, MIZ-1 and NTRK1 (TrkA). In addition, Hsp90 inhibition reduced HDAC6 expression and enhanced tubulin acetylation. Together our data suggest that Hsp90 inhibition suppresses the growth of neuroblastoma through multiple cellular pathways and that MYC/MYCN destabilization is among the important consequences of Hsp90 inhibition.

Citing Articles

Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics.

Ren K, Wang Y, Zhang M, Tao T, Sun Z Children (Basel). 2024; 11(11).

PMID: 39594898 PMC: 11593200. DOI: 10.3390/children11111323.

Proteomic analysis of serum small extracellular vesicles identifies diagnostic biomarkers for neuroblastoma.

Cheng J, Ji D, Ma J, Zhang Q, Zhang W, Yang L Front Oncol. 2024; 14:1367159.

PMID: 39228987 PMC: 11368728. DOI: 10.3389/fonc.2024.1367159.

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.

Valdez B, Yuan B, Murray D, Ramdial J, Popat U, Nieto Y Oncotarget. 2024; 15:220-231.

PMID: 38484153 PMC: 10939475. DOI: 10.18632/oncotarget.28563.

A Potential Prognostic Gene Signature Associated with p53-Dependent NTRK1 Activation and Increased Survival of Neuroblastoma Patients.

Currie D, Wong N, Zane I, Rix T, Vardakastanis M, Claxton A Cancers (Basel). 2024; 16(4).

PMID: 38398114 PMC: 10886603. DOI: 10.3390/cancers16040722.

Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma.

Shi X, Gao X, Liu W, Tang X, Liu J, Pan D Oncol Res. 2023; 31(4):569-590.

PMID: 37415742 PMC: 10319585. DOI: 10.32604/or.2023.028964.

References

Tang X, Evans A, Zhao H, Cnaan A, LONDON W, Cohn S . High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas. Clin Cancer Res. 1999; 5(6):1491-6. View

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

Nakagawara A, Scavarda N, Azar C, Cantor A, Brodeur G . Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993; 328(12):847-54. DOI: 10.1056/NEJM199303253281205. View

Combaret V, Gross N, Lasset C, Frappaz D, Peruisseau G, Philip T . Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol. 1996; 14(1):25-34. DOI: 10.1200/JCO.1996.14.1.25. View

Liu T, Laurell C, Selivanova G, Lundeberg J, Nilsson P, Wiman K . Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis. Cell Death Differ. 2006; 14(3):411-21. DOI: 10.1038/sj.cdd.4402022. View

Bagatell R, Beliakoff J, David C, Marron M, Whitesell L . Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer. 2004; 113(2):179-88. DOI: 10.1002/ijc.20611. View

Wanzel M, Kleine-Kohlbrecher D, Herold S, Hock A, Berns K, Park J . Akt and 14-3-3eta regulate Miz1 to control cell-cycle arrest after DNA damage. Nat Cell Biol. 2004; 7(1):30-41. DOI: 10.1038/ncb1202. View

Suzuki T, BOGENMANN E, Shimada H, Stram D, Seeger R . Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst. 1993; 85(5):377-84. DOI: 10.1093/jnci/85.5.377. View

Gross N, Bourloud K, Brognara C . MYCN-related suppression of functional CD44 expression enhances tumorigenic properties of human neuroblastoma cells. Exp Cell Res. 2000; 260(2):396-403. DOI: 10.1006/excr.2000.5007. View

10.

Smith M, Morton C, Phelps D, Kolb E, Lock R, Carol H . Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008; 51(1):34-41. DOI: 10.1002/pbc.21508. View

11.

Zajac M, Moneo M, Carnero A, Benitez J, Martinez-Delgado B . Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines. Mol Cancer Ther. 2008; 7(8):2358-66. DOI: 10.1158/1535-7163.MCT-08-0327. View

12.

Tang X, Zhao H, Robinson M, Cohen B, Cnaan A, LONDON W . Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A. 2000; 97(20):10936-41. PMC: 27127. DOI: 10.1073/pnas.190123297. View

13.

Sato S, Fujita N, Tsuruo T . Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A. 2000; 97(20):10832-7. PMC: 27109. DOI: 10.1073/pnas.170276797. View

14.

Nakamura Y, Ozaki T, Niizuma H, Ohira M, Kamijo T, Nakagawara A . Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line. Biochem Biophys Res Commun. 2007; 354(4):892-8. DOI: 10.1016/j.bbrc.2007.01.057. View

15.

Banerji U . Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 2009; 15(1):9-14. DOI: 10.1158/1078-0432.CCR-08-0132. View

16.

Schwab M, Varmus H, Bishop J, Grzeschik K, Naylor S, Sakaguchi A . Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature. 1984; 308(5956):288-91. DOI: 10.1038/308288a0. View

17.

Eggert A, Grotzer M, Ikegaki N, Evans A, Brodeur G . Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res. 2002; 62(6):1802-8. View

18.

Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H . Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001; 3(4):392-9. DOI: 10.1038/35070076. View

19.

Seeger R, Brodeur G, Sather H, Dalton A, Siegel S, Wong K . Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313(18):1111-6. DOI: 10.1056/NEJM198510313131802. View

20.

Goldschneider D, Horvilleur E, Plassa L, Guillaud-Bataille M, Million K, Wittmer-Dupret E . Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res. 2006; 34(19):5603-12. PMC: 1636465. DOI: 10.1093/nar/gkl619. View